secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0000950170-24-042789
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon nets ~$130M in PIPE; shares at $8.50, pre-funded warrants for 7.1M shares
--------------------------------------------------------------------------------

- Gross proceeds ~$130M from 8.235M shares at $8.50/share and 7.06M pre-funded warrants at $8.499/warrant.
- Pre-funded warrants exercisable at $0.001/share, immediately exercisable, no expiration.
- Investors include RA Capital, Perceptive Advisors, Paradigm BioCapital, Surveyor Capital, Sands Capital, Acorn Bioventures.
- Proceeds to fund ACR-368 registrational trials, ACR-2316, cell cycle program, AP3 platform, AI/ML; cash runway into H2 2026.
- Closing expected April 11, 2024; Jefferies acted as sole placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024042789/0000950170-24-042789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024042789/acrv-20240408.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-042789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer